Effect of a Dietary Fatty Acid Supplementation on Symptoms & Bronchial

Status Recruiting

Clinical Trial Summary

The proposed study will investigate the effect of a polyunsaturated fatty acid / lipid mixture (LCPUFAs) on the clinical symptoms, bronchial inflammation and lung function in allergic asthma in a bronchial allergen provocation (BAP) model. For this purpose, patients with stable episodic asthma and dust mite allergy will underwent BAP before and after supplementation with LCPUFAs. The clinical symptoms, bronchial inflammation, exhaled NO increase and lung function decline (FEV1) will be analyzed.

Clinical Trial Description

Asthma is a chronic lung disease, which is characterized by recurrent obstruction, a hypersensitivity and a chronic inflammation of the airway. It is known that LCPUVAs could reduce the production of inflammatory mediators. In addition, LCPUVAs can improve pulmonary function, with a concurrent reduction in bronchodilator use in patients with asthma. Subjects suffering from episodic asthma and house dust mite (HDM) allergy usually have a normal lung function testing at rest and show a decrease in lung function when they are exposed to HDM. Bronchial allergen provocation models are well established in asthma research and allow the evaluation of anti-allergic and anti-asthmatic agents in relatively small sample sizes. In a previous study the investigators could show, that LCPUVAs could reduce exhaled NO after repeated BAP with HDM.

In this study the investigators will investigate the protective effect of LCPUVAs in a repeated BAP model. Clinical symptoms (nasal and bronchial), exhaled NO, decrease in lung function the early asthmatic reaction (EAR), the late asthmatic reaction (LAR) and blood parameters (Triglyceride and Cholesterin and mircro RNAs) will be measured before and after LCPUVA supplementation. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04109534
Study type	Interventional
Source	Johann Wolfgang Goethe University Hospital
Contact	Stefan Zielen, Professor
Phone	+496301
Email	Stefan.Zielen@kgu.de
Status	Recruiting
Phase	N/A
Start date	October 1, 2019
Completion date	December 30, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03850626` - Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients
Completed	`NCT02911688` - Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure	Phase 2
Active, not recruiting	`NCT01776177` - The REALITY Study - a Real-life Long-term Analysis of Xolair Therapy	N/A
Completed	`NCT00485576` - Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma	Phase 2
Completed	`NCT00515775` - Influence of a Inhaled Corticosteroid Therapy Versus Corticosteroid + LABA Therapy on the FeNO of Asthmatic Children	N/A
Completed	`NCT00736801` - Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma	N/A
Completed	`NCT04259164` - Anti-inflammatory Effects Glycopyrronium	Phase 3
Active, not recruiting	`NCT04619017` - Airway Immune Response to Allergens (Use Lay Language Here)	Phase 1
Completed	`NCT01699594` - Change in Airway Responsiveness After Allergen Exposure	N/A
Completed	`NCT01353755` - 2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma	Phase 3
Completed	`NCT00999466` - The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen	Phase 2
Completed	`NCT00434434` - A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma	Phase 2
Completed	`NCT00492076` - Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma	Phase 4
Completed	`NCT00829179` - Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma	Phase 3
Completed	`NCT00490425` - Prevention of Asthma and Allergy by Probiotic Lactobacillus GG	Phase 4
Recruiting	`NCT04542902` - Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma	N/A
Active, not recruiting	`NCT05186025` - Tyrosine Allergoid Paediatric and Adult Study
Withdrawn	`NCT03307278` - House Dust Mite Induced Inflammasome Activation on Corticosteroid Resistance	N/A
Enrolling by invitation	`NCT06151938` - Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis
Withdrawn	`NCT04401631` - Analytical Validation of the abioSCOPE Device With an IgE Test Panel: Point-of-Care Precision, Sample Type Comparison and Method Correlation

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Effect of a Dietary Fatty Acid Supplementation on Symptoms and Bronchial Inflammation in Patients With Asthma — LCPUFA

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms